Epirubicin/paclitaxel/etoposide in extensive-stage small-cell lung cancer: a phase I–II study

The aim of this study was to evaluate feasibility and toxicity of escalating doses of epirubicin and paclitaxel plus fixed dose of etoposide and to define the activity of the triplet in extensive disease small-cell lung cancer. Thirteen patients entered the phase I study: the maximum tolerated doses...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Tibaldi, C, Prochilo, T, Russo, F, Pennucci, M C, Del Freo, A, Innocenti, F, Fabbri, A, Falcone, A, Conte, P F, Baldini, E
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Nature Publishing Group 2006
Konular:
Clinical Study
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC2361402/
https://ncbi.nlm.nih.gov/pubmed/16622468
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6603074
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller